What Is the Fadiman Protocol and Who Designed It
The Fadiman Protocol is a structured psilocybin microdosing schedule built on a strict 3-day repeating cycle: one day with a sub-perceptual dose, followed by two rest days, then repeat. Psychologist Dr. James Fadiman introduced the protocol around 2011 as a citizen-science research framework, describing it in his book The Psychedelic Explorer’s Guide. The protocol was not designed as a wellness product or clinical treatment — it was built around systematic self-observation to generate comparable data across a large number of self-selected participants.
Working with researcher Sophia Korb, Fadiman analyzed experience reports from more than 1,850 people across 30 countries, ranging in age from 18 to 77. The Fadiman Protocol has since become the most frequently cited microdosing schedule in published self-report research, which is why it appears as a reference point in most academic and journalistic discussions of microdosing.
This origin matters for reading the evidence correctly. The protocol’s structure reflects a research tool designed to produce consistent, trackable data — not a medically endorsed or clinically validated treatment. That distinction shapes how reported outcomes should be interpreted.
The 3-Day Cycle: How the Schedule Is Structured
The Fadiman Protocol follows a simple, repeating rhythm: dose on Day 1, rest on Days 2 and 3, then return to a dose day on Day 4. This pattern continues for an active period of typically 4 to 8 weeks, after which Fadiman recommends a 2 to 4 week break to allow for further tolerance reset and integration.
The table below shows how this repeating cycle maps across a three-week period:
| Day | Week 1 | Week 2 | Week 3 |
|---|---|---|---|
| Day 1 | Dose day | Rest day | Dose day |
| Day 2 | Rest day | Dose day | Rest day |
| Day 3 | Rest day | Rest day | Rest day |
| Day 4 | Dose day | Rest day | Dose day |
| Day 5 | Rest day | Dose day | Rest day |
| Day 6 | Rest day | Rest day | Rest day |
| Day 7 | Dose day | Dose day | Dose day |
Because the cycle repeats every 3 days rather than every 7, dose days shift across the week rather than falling on fixed calendar days. This is intentional — it keeps the pattern pharmacologically consistent rather than anchored to a social calendar.
In published citizen-science data, the typical psilocybin amount discussed in relation to the Fadiman Protocol is 0.1 to 0.3 grams of dried Psilocybe cubensis mushrooms, representing roughly 5 to 10 percent of what is generally considered a standard recreational dose. This range appears in the research as a descriptive average, not as a personal dosing prescription. A 2023 nationally representative survey found that approximately 47 percent of people who used psilocybin mushrooms in the past year reported microdosing as their mode of use during their most recent session, suggesting that sub-perceptual dosing has become a significant pattern of use even outside structured protocols.
Why Rest Days Matter: Tolerance and the Sub-Perceptual Goal
The two rest days in the Fadiman Protocol are the pharmacological foundation the entire schedule depends on. Psilocybin acts primarily on serotonin 5-HT2A receptors, and repeated stimulation of these receptors causes them to downregulate rapidly. A second dose taken within 24 hours of the first produces markedly reduced effects; full functional tolerance reset takes approximately 48 hours. The 1-on/2-off cadence is structurally the tightest schedule that allows each dose day to operate at full receptor sensitivity.
This tolerance mechanism is also why the sub-perceptual goal is central to the protocol’s design. A microdose within Fadiman’s framework is intended to produce effects that sit below the threshold of noticeable perception change — no visual alteration, no significant mood shift that disrupts normal functioning, no impairment. The Szigeti et al. 2021 placebo-controlled trial, one of the most cited controlled studies on psilocybin microdosing, defined a microdose operationally as 10 percent or less of the full dose needed to produce perceptible psychedelic effects. The Fadiman Protocol uses this sub-perceptual range as a target, not a starting point for escalation.
If a dose produces noticeable perceptual effects, it is generally considered too high within this framework. The rest days reinforce this by ensuring that each dose day begins from a fully reset baseline rather than a partially tolerant state — a partially tolerant state would require higher amounts to produce even a sub-threshold effect, which would defeat the purpose of the design.
Fadiman also treats daily journaling as an integral part of the protocol, not an optional extra. Participants are expected to track mood, energy, focus, anxiety, social interaction, sleep, and any unusual observations on dose days, rest days, and beyond. This self-monitoring serves two functions: it provides the observational data that the citizen-science framework depends on, and it gives the individual a structured way to detect whether the dose level, timing, or pattern needs adjustment. Without this tracking component, the protocol loses much of its research-tool character and becomes a simple dosing schedule.
Fadiman Protocol vs. Other Microdosing Schedules
The Fadiman Protocol is the most studied microdosing schedule in self-report research, but it is not the only structured approach. At least two other schedules appear frequently in discussions: the Stamets Stack and intuitive microdosing. Each reflects a different hypothesis about tolerance, integration, and how effects accumulate over time.
| Protocol | Schedule Structure | Key Distinguishing Feature |
|---|---|---|
| Fadiman Protocol | 1 day on / 2 days off, repeating 3-day cycle | Designed as a citizen-science research framework; emphasizes tolerance reset and daily journaling |
| Stamets Stack | 4 days on / 3 days off | Typically combines psilocybin with lion’s mane mushroom and niacin; developed by mycologist Paul Stamets |
| Intuitive Microdosing | No fixed schedule; dose based on daily self-assessment | No structured cycle; relies entirely on the individual’s own judgment about when to dose |
The structural differences between these schedules reflect genuinely different assumptions. The Fadiman Protocol prioritizes a clean pharmacological reset between doses. The Stamets Stack uses a longer consecutive dosing period paired with functional mushroom supplements — lion’s mane is a legal functional mushroom and a distinct substance from psilocybin — based on a different hypothesis about cumulative neurological effects. Intuitive microdosing abandons fixed scheduling entirely, which produces no comparable or trackable pattern for research purposes.
None of these schedules has demonstrated superiority over the others in controlled clinical settings. The comparison above is informational — different structures, different rationales, and currently an insufficient evidence base to declare any one approach safer or more effective than another.
Legal Status, Safety Context, and Research Limitations
Psilocybin is a Schedule I controlled substance under U.S. federal law, classified as having no currently accepted medical use and a high potential for abuse at the federal level. Possession, distribution, and use remain federally illegal in the United States regardless of state-level variation. Oregon and Colorado have established regulated state-level programs where psilocybin can be accessed in supervised contexts, but these programs operate under specific legal frameworks and do not constitute general legal authorization for personal microdosing use.
Outside the United States, psilocybin remains illegal in most countries. Legal status varies significantly by jurisdiction, and anyone interested in this topic should verify the laws applicable to their specific location.
On the evidence side, two different types of data should be distinguished. The citizen-science data from Fadiman’s project — including self-tracked reports of improved focus, mood, reduced anxiety, and enhanced creativity — is observational and self-reported. Participants self-selected, doses were not verified, and there were no controls for placebo effects or confounding factors. These reports are valuable as a source of hypotheses and scale, but they do not constitute clinical proof of benefit.
Controlled clinical evidence for psilocybin microdosing specifically remains preliminary and mixed. The Szigeti et al. 2021 study is among the most methodologically notable attempts to examine microdosing under more controlled conditions, using a self-blinding design to limit expectation effects. Its findings were more cautious than citizen-science reports suggest, with expectation effects playing a significant role. No regulatory body has approved psilocybin microdosing as a treatment for any condition.
People with personal or family histories of psychosis, schizophrenia, or bipolar disorder, those taking serotonergic medications such as SSRIs or MAOIs, and individuals with other significant health conditions should be particularly cautious. Self-experimenting with psilocybin carries real pharmacological and legal risks. A qualified medical or legal professional is the appropriate source of personal guidance on these questions.
Frequently Asked Questions
Does the Fadiman Protocol work if dose days don’t fall on the same day each week?
Yes — that is by design. Because the cycle repeats every 3 days rather than every 7, dose days rotate through the week continuously. The Fadiman Protocol is built around pharmacological consistency, not calendar alignment. Expecting dose days to fall on the same weekday each week reflects a misunderstanding of the structure.
Is journaling required, or just recommended?
Within Fadiman’s original framework, journaling is a core component of the protocol, not optional. The citizen-science data that underpins the protocol was built from structured self-reports. Without systematic tracking, the observational purpose of the design is lost, and it becomes harder to distinguish genuine effects from expectation, placebo, or other variables.
What distinguishes the Fadiman Protocol from the Stamets Stack?
The primary structural difference is the schedule: the Fadiman Protocol uses a 1-on/2-off cycle; the Stamets Stack uses 4 days on followed by 3 days off. The Stamets approach also typically combines psilocybin with lion’s mane mushroom and niacin, based on a different hypothesis about synergistic neurological effects. Lion’s mane is a legal functional mushroom supplement and is a distinct substance from psilocybin — the two should not be conflated.
Can the Fadiman Protocol be used legally anywhere?
Psilocybin use outside regulated programs is illegal at the U.S. federal level and in most countries. Oregon and Colorado have regulated supervised access programs, but these are not designed around personal microdosing schedules. There is currently no jurisdiction where unregulated personal psilocybin microdosing is clearly legal under a standard consumer or wellness framework.
